Economical production of artemisinin precursors

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$597,202.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI061936-01
Award Id:
71268
Agency Tracking Number:
AI061936
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
AMYRIS BIOTECHNOLOGIES, 412 B KAINS AVE, ALBANY, CA, 94706
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
JACK NEWMAN
(510) 504-3995
NEWMAN@AMYRISBIOTECH.COM
Business Contact:
(510) 504-3995
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): In many regions of the world, strains of Plasmodium have emerged that are resistant to the current arsenal of antimalarial therapeutics. Artemisinins, terpenoid compounds derived from traditional Chinese medicines used for centuries, have been acclaimed as the next generation of antimalarial drugs because they show little or no cross-resistance with existing antimalarials. While inexpensive by Western standards, artemisinin based treatments remain prohibitively expensive to those in the developing world who need them most. The long term goal of this SBIR-at-NIAID project is to develop an artemisinin production process utilizing a biosynthetically produced synthon, artemisinic acid. Methods for the synthesis of artemisinin from artemisinic acid currently exist, but are not utilized due to the cost of extracting the precursor. This Phase I project will address this problem by proving the feasibility of producing artemisinic acid via a bacterial fermentation. Building on previous work which enabled the production of the artemisinic acid precursor, amorphadiene, at high levels, we will build a production strain that is able to produce economically relevant levels of amorphadiene. We will also isolate, clone, and express the genes, likely encoding cytochrome P450s, responsible for the conversion of amorphadiene to artemisinic acid. Additionally, we will engineer the machinery for efficient catalysis by P450s in E. coli. This research, conducted in collaboration with the University of California, could eventually lead to reductions in the cost of artemisinin based treatments by a factor of 3 or more. This technology could also result in the development of many promising new terpene-based drugs produced at a lower cost to consumers, reduced time to market, and to decreased effect on the environment, in terms of destruction of natural resources and the release of synthetic chemical effluents.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government